Middle East Respiratory Syndrome (MERS) Drug Pipeline Market Insights Report 2022: 12+ Companies and 12+ Pipeline Drugs in the Pipeline Landscape – ResearchAndMarkets.com – Business Wire

DUBLIN–(BUSINESS WIRE)–The “Middle East respiratory syndrome – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

The “Middle East Respiratory Syndrome – Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Middle East Respiratory Syndrome commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Middle East Respiratory Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Middle East Respiratory Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Middle East Respiratory Syndrome.
Middle East Respiratory Syndrome Emerging Drugs Chapters
This segment of the Middle East Respiratory Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Middle East Respiratory Syndrome Emerging DrugsINO-4700: Inovio pharmaceuticals
INO-4700 (GLS-5300) is a DNA plasmid vaccine that expresses the MERS-CoV spike (S) glycoprotein and was co-developed by GeneOne Life Science Inc. and Inovio Pharmaceuticals. The INO-4700 MERS-CoV product is a DNA vaccine candidate, allowing rapid design and production in response to emerging infectious diseases. Underscoring the potential for rapid deployment of DNA vaccines, INO-4700 was advanced into the clinic within nine months of preclinical vaccine candidate selection. INOVIO’s Phase II trial is designed to evaluate INO-4700, its DNA vaccine candidate for the prevention of MERS, a disease in the coronavirus family for which there are no approved vaccines.
VTP-500: Vaccitech
VTP-500 (ChAdOx1) is a vaccine candidate in Phase I clinical trials that protects people against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the novel SARS-CoV-2 coronavirus. Vaccitech’s VTP-500 MERS vaccine utilizes the ChAdOx1 virus platform to encode MERS coronavirus spike protein to induce T cells and antibodies that block virus-host cell receptor binding and fusion or neutralize virus infection.
Middle East Respiratory Syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Middle East Respiratory Syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Middle East Respiratory Syndrome
There are approx. 12+ key companies which are developing the therapies for Middle East Respiratory Syndrome. The companies which have their Middle East Respiratory Syndrome drug candidates in the most advanced stage, i.e. Phase II include, Inovio pharmaceuticals.
PhasesThe report covers around 12+ products under different phases of clinical development like
Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Middle East Respiratory Syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Middle East Respiratory Syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Middle East Respiratory Syndrome drugs.
Middle East Respiratory Syndrome Report Insights
Middle East Respiratory Syndrome Report Assessment
Key Players
Key Products
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/xx60om
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

source

Add a Comment

Your email address will not be published. Required fields are marked *